Statistical analysis revealed that FOLFOXIRI + C demonstrated a superior PFS benefit compared to FOLFOX + B(HR=0.84, 95% CI 0.38-1.89), FOLFIRI + B (HR=0.68, 95% CI 0.22-2.01), FOLFOX + C (HR=0.91, 95% CI 0.48-1.65), FOLFIRI + C (HR=0.67, 95% CI 0.24-1.79), FOLFOX + P (HR=0.81, 95% CI 0.37-1.69), FOLFIRI + P (HR=0.90, 95% CI 0.31-2.54), FOLFOXIRI + P (HR=0.83, 95% CI 0.35-1.71), FOLFOX (HR=0.63, 95% CI 0.28-1.32), FOLFIRI (HR=0.70, 95% CI 0.37-1.32), and FOLFOXIRI (HR=0.72, 95% CI 0.35-1.37); however, the differences failed to reach statistical significance.
← all excerpts
Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis.
1
—
—